Aktieanalyser från populära analyshus

Senaste aktieanalyserna

Polygiene Group Q4 2024: Strong beat on both top-line and profitability - Redeye

Analys | Redeye

•

13 Feb 09:31

Polygiene Group Q4 2024: Strong beat on both top-line and profitability - Redeye

CapMan: Solid underlying Q4 with boost from positive fair value changes - Nordea

CapMan’s underlying performance in Q4 was solid and slightly above our estimates.

CapMan

Analys | ABG Sundal Collier

•

13 Feb 09:31

Nilörngruppen: A long-awaited return to normal volumes - ABG

Xspray Pharma Q4 2024: In anticipation of an eventful year - Redeye

Redeye provides an update on Xspray Pharma following its year-end report, which revealed no major su...

G5 Entertainment Q4 2024: Solid year-end performance - Redeye

Atria: Soft Q4 and a negative guidance for 2025 - Nordea

Atria reported Q4 adjusted EBIT of EUR 13.2m, 19% (EUR 3.

Carasent Q4: Slightly Softer than Expected - Redeye

Neola Medical Q4: Vital clinical data incoming - Redeye

Redeye provides an update following Neola Medical’s Q4 2024 report.

Taaleri: Solid end to a turbulent year - Nordea

NoHo Partners: Breaking records even in a lower cycle - Nordea

NoHo Partners' Q4 2024 results came in clearly above Vara Research consensus, as the company continu...

Vertiseit: Integration and North America in Focus - Redeye

Vertiseit

Analys | ABG Sundal Collier

•

13 Feb 07:17

Medicover: Story continues, but without Mr Rågmark - ABG

Small beat in Q4 and news of CEO leaving Adj. EBITDA up 2.

Smart Eye: Brace for design win season - Redeye

Smart Eye

Analys | Analyst Group

•

12 Feb 18:46

Comment on Eevia Health’s Term Sheet Agreement with an International Partner and the Announced Insider Transactions - Analyst Group

On February 12th, Eevia Health Plc (publ) (“Eevia”) announced that the Company has signed a term she...

Eevia Health

Analys | Analysguiden

•

12 Feb 18:45

New Wave Group: Bra resultat i en utmanande marknad - Analysguiden

Etteplan: Soft as was expected - Evli

Etteplan’s Q4 performance aligned with our expectations.

Alisa Bank: Year of opportunities ahead - Evli

Marimekko: Outlook in focus - Evli

Marimekko reports its Q4/24 figures on 19th of February.

Marimekko

Analys | ABG Sundal Collier

•

12 Feb 12:44

Ferronordic: Germany likely stagnant, but US strong - ABG

Ferronordic

Analys | ABG Sundal Collier

•

12 Feb 12:43

Infrea: Stable end to the year - ABG

Q4 report Wednesday, 19 February at 08:30 CET '24e EBITA up 4% 25-9x EBITA in '24e-'26e, 5-18% FCF y...

Infrea

Analys | ABG Sundal Collier

•

12 Feb 12:43

Nilörngruppen: Beats on sales and earnings - ABG

NoHo Partners: Strong Q4 results point to a solid 2025 - Nordea

NoHo Partners reported Q4 EBIT of EUR 15.1m (+42%% y/y), 19% above Vara Research consensus and 13% a...

Catella Q4 2024: Overall solid, strong set-up for 2025 - Redeye

Taaleri: Solid underlying performance across the board - Nordea

Taaleri’s group continuing earnings grew 6% y/y to EUR 10.

Taaleri

Analys | ABG Sundal Collier

•

12 Feb 12:40

Medicover: Small beat but negative to see CEO leaving - ABG

Sprint Bioscience: Confident expansion - Redeye

Sprint Bioscience delivered Q4 sales within the recent range at SEK 16.

Sprint Bioscience

Analys | ABG Sundal Collier

•

12 Feb 12:38

Catella: Q4 beat driven by Corporate Finance - ABG

Catella

Analys | ABG Sundal Collier

•

12 Feb 12:37

IRLAB Therapeutics Q4 report: driving IRL757 development - ABG

Pirepemat topline data coming closer IRL757 passes Ph 1 successfully Webcast today at 10:00 CET Eve...

Vertseit Q4: High Sales and Cost – EBITDA-CAPEX 5% Above Expectations - Redeye

Premium Snacks: Rapportkommentar Q4'24 - Kalqyl

Nettoomsättningen för det tredje kvartalet uppgick till 119,6 MSEK (99,8), vilket motsvarade en orga...

Premium Snacks

Föregående Nästa